Data MATRIX team is starting an international phase I study to be conducted in Russia and the United States.
Data MATRIX team is starting an international phase I study to be conducted in Russia and the United States.
MATRIX EDC was chosen as the primary technology for data collection and management, which meets all necessary requirements. This will be a multicenter open study for patients with hematological malignancies. It is planned to enroll up to 110 participants.
This project is already the third rescue study for Data MATRIX, when the team takes over data collection and management tasks on MATRIX EDC from another provider. ‘We appreciate the fact that American CROs and sponsors have chosen Data MATRIX several times now to help deliver on time and on budget, even in such a competitive market as the US’, – says Data MATRIX CEO Ivan Dobromyslov.
The study will be completed in 2020.
Data MATRIX is a unique provider for software, data management and biostatistics services for clinical trials. Since 2009, Data MATRIX has been offering EDC/IWRS, Data Management, Statistical analysis and Medical writing. The team has successfully conducted more than 160 clinical trials using MATRIX EDC/IWRS and received highly positive feedback from the clients. The company has offices in US, Germany and Russia, where it is #1 DM company.